Literature DB >> 2421949

Determination in human cerebrospinal fluid of glial fibrillary acidic protein, S-100 and myelin basic protein as indices of non-specific or specific central nervous tissue pathology.

M Noppe, R Crols, D Andries, A Lowenthal.   

Abstract

The nervous system specific proteins glial fibrillary acidic protein (GFAp), S-100 and myelin basic protein (MBP) were determined in 535 human cerebrospinal fluid (CSF) samples. The level of all three proteins was increased in CSF of patients with nonselective destructive central nervous tissue disease such as encephalitis, cerebrovascular disease or tumoural compression. The increases in GFAp were more constant, making it a better marker of CNS pathology. Increases in MBP in CSF of patients with acute demyelinating disease were confirmed. S-100 did not seem to give more information as GFAp. Isolated increases of GFAp could be demonstrated in patients with dementia (Alzheimer type or multi-infarct dementia) or syringomyelia. Since CNS of these patients is very rich in fibrillary astrocytes, containing large amounts of GFAp, it is suggested that GFAp is to be considered as a specific marker of fibrillary gliosis in CSF and can be used as a diagnostic tool in dementia and syringomyelia.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2421949     DOI: 10.1016/0009-8981(86)90275-5

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  13 in total

1.  Longitudinal study of differential protein expression in an Alzheimer's mouse model lacking inducible nitric oxide synthase.

Authors:  Michael D Hoos; Brenna M Richardson; Matthew W Foster; Angela Everhart; J Will Thompson; M Arthur Moseley; Carol A Colton
Journal:  J Proteome Res       Date:  2013-09-18       Impact factor: 4.466

2.  Letter to the Editor.

Authors:  Mahsa Abassi; Ned Sacktor
Journal:  J Neurovirol       Date:  2019-07-05       Impact factor: 2.643

3.  TNF alpha affects the expression of GFAP and S100B: implications for Alzheimer's disease.

Authors:  M M Edwards; S R Robinson
Journal:  J Neural Transm (Vienna)       Date:  2006-06-01       Impact factor: 3.575

4.  LINGO-1 antibody ameliorates myelin impairment and spatial memory deficits in the early stage of 5XFAD mice.

Authors:  Di Wu; Xiang Tang; Li-Hua Gu; Xiao-Li Li; Xin-Yang Qi; Feng Bai; Xiao-Chun Chen; Jian-Zhi Wang; Qing-Guo Ren; Zhi-Jun Zhang
Journal:  CNS Neurosci Ther       Date:  2018-02-09       Impact factor: 5.243

5.  Increased cerebrospinal fluid levels of glial fibrillary acidic protein (GFAp) in Lyme neuroborreliosis.

Authors:  L Dotevall; L E Rosengren; L Hagberg
Journal:  Infection       Date:  1996 Mar-Apr       Impact factor: 3.553

6.  Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis.

Authors:  M Axelsson; C Malmeström; S Nilsson; S Haghighi; L Rosengren; J Lycke
Journal:  J Neurol       Date:  2011-01-01       Impact factor: 4.849

Review 7.  Heart-fatty acid-binding protein as a marker for early detection of acute myocardial infarction and stroke.

Authors:  Pierre Lescuyer; Laure Allard; Denis F Hochstrasser; Jean-Charles Sanchez
Journal:  Mol Diagn       Date:  2005

8.  Immunohistochemical localization of S-100 protein, glial fibrillary acidic protein, and neuron-specific enolase in the pars distalis of quail, rat, and human hypophyses.

Authors:  L Van Nassauw; F Harrisson; P Cras; M Callebaut
Journal:  Histochemistry       Date:  1987

9.  Molecular biomarkers in stroke diagnosis and prognosis.

Authors:  Matthew B Maas; Karen L Furie
Journal:  Biomark Med       Date:  2009-08-01       Impact factor: 2.851

10.  GFAP isoforms in adult mouse brain with a focus on neurogenic astrocytes and reactive astrogliosis in mouse models of Alzheimer disease.

Authors:  Willem Kamphuis; Carlyn Mamber; Martina Moeton; Lieneke Kooijman; Jacqueline A Sluijs; Anne H P Jansen; Monique Verveer; Lody R de Groot; Vanessa D Smith; Sindhoo Rangarajan; José J Rodríguez; Marie Orre; Elly M Hol
Journal:  PLoS One       Date:  2012-08-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.